‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?

Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettinger, Claire, Livings, Claire, Grochot, Rafael, Furness, Andrew, Lopez, Juanita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791423/
https://www.ncbi.nlm.nih.gov/pubmed/36564127
http://dx.doi.org/10.1136/jitc-2022-006073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791423/
https://www.ncbi.nlm.nih.gov/pubmed/36564127
http://dx.doi.org/10.1136/jitc-2022-006073

Ejemplares similares